Combination Artemisinin and Chemiluminescent Photodynamic Therapy for Treatment of Malaria and Cancer

**Background:**
Malaria, mainly caused by *Plasmodium falciparum*, results in over 200 million clinical cases a year and approximately 430,000 deaths a year. Tropical and sub-tropical countries have a high incidence of malaria cases because *Anopheles* mosquitoes thrive in warm temperatures and are able to efficiently transmit the disease. Direct costs associated with malaria are estimated to be 12 billion US dollars a year with indirect costs being many times higher.

**Technology Description:**
Researchers at Washington University have developed and validated a method for treating malaria using a novel combination of therapeutics. This method, called Photodynamic Therapy (PDT), integrates artemisinin, a frontline anti-malarial, as an activator with 5-aminolevulinic acid which is a photosensitizer. This combination emits toxic oxygen radicals when exposed to light emitted by luminol in order to kill intra-erythrocytic and blood-stage parasites. Preliminary data indicate potent anti-malarial activity in *ex vivo* cultures of the parasite in red blood cells. Furthermore, 5-aminolevulinic acid has been used as a PDT photosensitizer to treat cancer and the proposed combination could be utilized to treat cancer, especially hematologic cancers.

**Key Advantages:**
- Low toxicity and low cost
- Decreased dosage amount due to synergy
- Could possibly be used to overcome artemisinin resistance
- Potentially favorable regulatory path
- Useful for deep tissues and hard-to-reach areas
- Targets multiple types of cancer

**Patent/Patent Application:** US20160367674A1

**Lead Inventor:**
Daniel E. Goldberg M.D., Ph.D. (Internal Medicine/Infectious Disease)

---

**Licensing Contact**
David Silva, Ph.D
dsilva@wustl.edu
314-747-0923

**Application Space**
Therapeutic, Malaria, Cancer

**WUSTL Case#**
015173